Autophagic clearance of aggregate-prone proteins associated with neurodegeneration.

Methods Enzymol

Department of Medical Genetics, University of Cambridge, Cambridge Institute for Medical Research, Addenbrooke's Hospital, Cambridge, UK.

Published: April 2009

Autophagy has emerged as a field of rapidly growing interest with implications in several disease conditions, such as cancer, infectious diseases, and neurodegenerative diseases. Autophagy is a major degradation pathway for aggregate-prone, intracytosolic proteins causing neurodegenerative disorders, such as Huntington's disease and forms of Parkinson's disease. Up-regulating autophagy may be a tractable therapeutic intervention for clearing these disease-causing proteins. The identification of autophagy-enhancing compounds would be beneficial not only in neurodegenerative diseases but also in other conditions where up-regulating autophagy may act as a protective pathway. Furthermore, small molecule modulators of autophagy may also be useful in dissecting pathways governing mammalian autophagy. In this chapter, we highlight assays that can be used for the identification of autophagy regulators, such as measuring the clearance of mutant aggregate-prone proteins or of autophagic flux with bafilomycin A(1). Using these methods, we recently described several mTOR-independent autophagy-enhancing compounds that have protective effects in various models of Huntington's disease.

Download full-text PDF

Source
http://dx.doi.org/10.1016/S0076-6879(08)04005-6DOI Listing

Publication Analysis

Top Keywords

aggregate-prone proteins
8
neurodegenerative diseases
8
huntington's disease
8
up-regulating autophagy
8
autophagy-enhancing compounds
8
autophagy
7
autophagic clearance
4
clearance aggregate-prone
4
proteins
4
proteins associated
4

Similar Publications

Article Synopsis
  • Protein quality control (PQC) is essential for the function of heart cells, and certain mutations (like R120G in CRYAB and P209L in BAG3) can lead to the buildup of harmful protein aggregates and heart diseases.
  • The study explored how these protein aggregates are taken up by mitochondria and removed through a process called mitophagy, especially in mice lacking the TRAF2 protein, which is necessary for mitophagy.
  • Results showed that without TRAF2, there was an increase in protein aggregates and misplacement of other proteins, indicating that proper mitophagy is critical for preventing cardiac dysfunction.
View Article and Find Full Text PDF
Article Synopsis
  • * Resveratrol was studied for its impact on amylin aggregation and the formation of extracellular vesicles in pancreatic β cells and hippocampal cells.
  • * The research found that resveratrol reduced amylin aggregation and the size of toxic exosomes, thereby lessening their harmful effects on neurons.
View Article and Find Full Text PDF

One of the main hallmarks of Parkinson's disease (PD) pathology is the spread of the aggregate-prone protein α-synuclein (α-syn), which can be detected in the plasma and cerebrospinal fluid of patients as well as in the extracellular environment of neuronal cells. The secreted α-syn can exhibit "prion-like" behavior and transmission to naïve cells can promote conformational changes and pathology. The precise role of plasma membrane proteins in the pathologic process of α-syn is yet to be fully resolved.

View Article and Find Full Text PDF

Increasing evidence suggests an essential function for autophagy in unconventional protein secretion (UPS). However, despite its relevance for the secretion of aggregate-prone proteins, the mechanisms of secretory autophagy in neurons have remained elusive. Here we show that the lower motoneuron disease-associated guanine exchange factor Plekhg5 drives the UPS of Sod1.

View Article and Find Full Text PDF
Article Synopsis
  • Huntington's disease (HD) is a hereditary neurodegenerative disorder characterized by movement issues and cognitive/psychiatric symptoms, caused by a mutation in the huntingtin gene leading to toxic protein accumulation.
  • A clinical trial named FELL-HD is underway to test the safety and tolerability of the drug felodipine, selected for its ability to induce autophagy and degrade the mutant huntingtin protein in early HD patients.
  • This phase II trial will follow 18 participants over 58 weeks, measuring adverse events and various health outcomes, and has received ethical approval and regulatory clearance for the study's conduct.
View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!